Dow Jones Newswires

BioCryst Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

6/30/2026, 08:15 PM GMT+8 Dow Jones Newswires

(12:15 GMT) BioCryst Pharmaceuticals Price Target Raised to $29.00/Share From $27.00 by Cantor Fitzgerald